FrontRow · Nov 19, 2026
FrontRow — photo status
Pharma major Novartis is becoming more optimistic about some of its biggest growth drugs, even as investors question the company's ability to sustain growth beyond 2031 and offset the financial impact of older drugs' patent expiries. The Swiss drugmaker now expects multiple sclerosis drug Kesimpta, leukaemia treatment Scemblix, and cholesterol medicine Leqvio to generate $18 billion in peak sales, up from a previous forecast of $14 billion combined. CEO Vas Narasimhan said the upgrades were driven primarily by strong commercial performance, pointing to growing market share for Kesimpta and Scemblix and robust demand for Leqvio in the U.S. and Asia. "It's really that in-market commercial performance that's driving these upgrades," Narasimhan told reporters on Thursday.
More from FrontRow
- FrontRowNov 22, 2026

- FrontRowNov 22, 2026 · Ford has started U.S. production and shipments of battery ce

- FrontRowNov 21, 2026

- FrontRowNov 21, 2026 · Anthropic held its historic Nasdaq debut on Thursday, raisin

- FrontRowNov 21, 2026

- FrontRowNov 21, 2026 · The era of U.S. airlines' long-haul, international first cla
